Can a horse advertise erection drugs? Aflofarm's new campaign proves that it surely can! The first of a series of commercial spots for the erection medicine Inventum Max premiered on 20th June. The campaign takes a tongue-in-cheek approach towards erectile dysfunction, which is a common problem among men.
A departure from the standard scheme of advertising erectile dysfunction products, a completely new line of communication and an unusual humorous accent in the form of a talking horse - this is how the Inventum Max advertising campaign is presented in brief. Extensive activities including digital media and television have been launched in the second half of June 2021, and outdoor activities are planned for the upcoming future.Click to see the ad!
How does a horse know what a horse dose of erection dysfunction medicine is?
"Horse dose of erectile dysfunction medicine" - this is one of the slogans appearing in the campaign, the most characteristic element of which is a horse joining the conversation, seeming perfectly familiar with the subject matter. The animal, due to its rich symbolism - including triumph, sensuality and fertility, refers to male strength and sexual prowess.
- The concept of the Inventum Max campaign was based on an idea different than the one usually applied to products improving the quality of sexual life. Limiting the scenes depicting intimate relations between men and women, we decided to focus on a relaxed conversation in which the horse is an active participant. By doing so, we want to introduce the topic of erectile dysfunction into the realm of problems that should be discussed with more distance and freedom – asserts Filip Beck, Senior Brand Manager at Aflofarm Farmacja Polska, responsible for the product.
The first ad lasts 30 seconds and has been broadcast on major TV stations since 20th June. Soon there will also be a second ad in this series. Aflofarm Farmacja Polska is responsible for both the creation and execution, while Starcom Media House is responsible for the planning and purchase of advertising space.
- We also feel obliged to emphasize that no animals were harmed during the filming of the commercials. The horse involved in the commercial was extremely proud of his role. Unfortunately due to GDPR we cannot mention his name... This is a joke of course! However, we would actually prefer not to disclose his details for fear of being bought by competition - concludes Filip Beck, Aflofarm Farmacja Polska.
Before use, read the leaflet, which includes indications, contraindications, data on adverse reactions and dosage, and information on the use of the medicinal product, or consult your doctor or pharmacist, as any medicine used inappropriately poses a risk to your life or health.
Before taking Inventum Max, make sure that the medicine is intended for you. To do this, complete the Diagnostic Test included in the leaflet.
Inventum Max, 50 mg, chewable tablets. Each tablet contains 50 mg of sildenafil formed in situ from 70.24 mg of sildenafil citrate. Excipients of known effect: aspartame, lactose monohydrate, sodium, potassium. Indications for use: The medicinal product is indicated for use in adult men with erectile dysfunction, which is the inability to obtain or maintain a penile erection sufficient for sexual intercourse. Sexual stimulation is necessary for the medicinal product to work effectively. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Due to the effect of sildenafil on the metabolic pathways involving nitric oxide and cyclic guanosine monophosphate (cGMP), it enhances the hypotensive effect of nitrates. Concomitant use of sildenafil with nitric oxide-releasing drugs (such as amyl nitrite) or nitrates in any form is therefore contraindicated. Concomitant use of PDE5 inhibitors, including sildenafil, and drugs that stimulate guanylate cyclase, such as riociguat, is contraindicated because it may lead to symptomatic hypotension. Medicinal products for the treatment of erectile dysfunction, including sildenafil, should not be used in men in whom sexual activity is not indicated (e.g. patients with severe cardiovascular disease such as unstable angina or severe heart failure). The medicinal product is contraindicated in patients who have lost vision in one eye as a result of non-arteritic anterior ischaemic optic neuropathy (NAION) regardless of whether this was related or unrelated to prior exposure to a PDE5 inhibitor. The safety of sildenafil has not been studied in the following patient groups: patients with severe hepatic insufficiency, hypotension (blood pressure < 90/50 mmHg), recent stroke or myocardial infarction, and inherited retinal degenerative changes such as retinitis pigmentosa (a small proportion of these patients have genetically determined retinal phosphodiesterase abnormalities). The use of sildenafil in these patients is contraindicated. Responsible entity: Aflofarm Farmacja Polska Sp. z o.o., Partyzancka 133/151, 95-200 Pabianice
